Robert N. Schuck

发表

Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling

Robert N. Schuck, Joseph A. Grillo, 2016, The AAPS Journal.

Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling

J. Grillo, Robert N. Schuck, R. Schuck, 2016, The AAPS Journal.

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 fusion or other rearrangement.

Jiang Liu, L. Fashoyin-Aje, Martha Donoghue, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer

S. J. Schrieber, Chao Liu, Richard Pazdur, 2017, Clinical Cancer Research.

Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients.

K. Tomer, G. Stouffer, D. Zeldin, 2013, Atherosclerosis.

Biomarkers in drug development

J. Wagner, J. Delfino, Robert N. Schuck, 2022, Atkinson's Principles of Clinical Pharmacology.

Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism.

S. Poloyac, Craig R. Lee, A. Oni‐Orisan, 2012, American journal of physiology. Endocrinology and metabolism.

Beyond Statins: Lipid Management to Reduce Cardiovascular Risk

R. Simpson, Robert N. Schuck, P. Mendys, 2013, Pharmacotherapy.

New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

B. Dickerson, W. Marks, B. Boeve, 2019, Alzheimer's & Dementia.

Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice.

K. Tomer, Kimberly C. Molnar, D. Zeldin, 2013, Prostaglandins & other lipid mediators.

Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) Is Associated With Forearm Vasodilator Responses in Humans

D. Zeldin, N. Brown, Craig R. Lee, 2011, Hypertension.

Translational Characterization of Arachidonic Acid Metabolism in Vascular Inflammation and Cardiovascular Disease

Robert N. Schuck, R. Schuck, 2013 .

Dose-finding studies in drug development for rare genetic diseases

M. Pacanowski, Jie Wang, Robert N. Schuck, 2022, Orphanet Journal of Rare Diseases.

Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity

K. Tomer, K. Hua, J. Falck, 2014, Journal of Lipid Research.

Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease.

G. Stouffer, Craig R. Lee, Robert N. Schuck, 2018, Prostaglandins & other lipid mediators.

Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease.

J. Schisler, B. Jensen, Eleanor G. Hilliard, 2017, The American journal of pathology.

Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease.

K. Tomer, G. Stouffer, D. Zeldin, 2012, Atherosclerosis.

Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice

K. Tomer, J. Foley, J. Falck, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

The Cytochrome P450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease

K. Tomer, D. Zeldin, M. Edin, 2014, PloS one.

The Cytochrome P 450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease

K. Tomer, D. Zeldin, M. Edin, 2014 .

Clinical and Regulatory Considerations for Pharmacogenetic Testing

M. Pacanowski, Robert N. Schuck, Hobart L Rogers, 2019 .

Clinical and regulatory considerations in pharmacogenetic testing.

M. Pacanowski, Robert N. Schuck, R. Schuck, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A Systematic Assessment of US Food and Drug Administration Dosing Recommendations For Drug Development Programs Amenable to Response‐Guided Titration

I. Zineh, R. Madabushi, K. Maxfield, 2020, Clinical pharmacology and therapeutics.

Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.

Norman Stockbridge, Rajanikanth Madabushi, Michael Pacanowski, 2015, Circulation.

Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) Is Associated With Forearm Vasodilator Responses in Humans

D. Zeldin, N. Brown, Craig R. Lee, 2011, Hypertension.

Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers

I. Zineh, A. Shuldiner, R. Horenstein, 2014, Journal of clinical pharmacology.

Considerations for Developing Targeted Therapies in Low‐Frequency Molecular Subsets of a Disease

I. Zineh, J. Woodcock, R. Charlab, 2018, Clinical pharmacology and therapeutics.

Leveraging in Vitro Models for Clinically Relevant Rare CYP2D6 Variants in Pharmacogenomics

Robert N. Schuck, P. Hyland, Sydney Stern, 2024, Drug Metabolism and Disposition.